Endo announces update on Phase III-program for Orexo´s pain product Rapinyl™

On November 1 2007, Orexo´s licensing partner Endo Pharmaceuticals has, in connection with the announcement of their Interim Report, left the following information:

“RAPINYL™. The company announced that, due to the continued challenge of recruiting cancer patients in its Phase III placebo-controlled efficacy trial of this sublingual fentanyl tablet being studied for the treatment of breakthrough cancer pain, it has decided that it will conduct an interim statistical analysis of this trial. This interim analysis will be conducted as soon as possible when a predetermined number of patients (based upon a power calculation) with evaluable data have completed the trial. The company will provide further updates when this analysis is completed.”